Take three: after the Cantonese and modern Asian menus failed to resonate, Perry’s multi-storey Double Bay site will be ...

A hamburger bun can make or break your burger, so it's important to make the right selection. We tasted a variety of store-bought options and ranked them.

HC Wainwright raised their target price on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, June 2nd.

Piper Sandler raised the firm’s price target on Verona Pharma (VRNA) to $160 from $76 and keeps an Overweight rating on the shares. Verona Pharma remains one of Piper’s top 2025 picks, where ...

Piper Sandler also reiterated an Overweight rating with a $76.00 price target, highlighting Verona Pharma's strategic expansion of its sales force and direct-to-patient advertising efforts.

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating. The adjustment ...

In other recent news, Verona Pharma's Ohtuvayre has shown strong sales performance, with Jefferies reporting a significant increase to $71 million in the first quarter of 2025 from $37 million in the ...

Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst insights, and future rally potential.

Experience the grandeur of the Arena di Verona from the sky, capturing its ancient Roman architecture, iconic elliptical ...

Jefferies raised its price target on Verona Pharma (NASDAQ: VRNA) stock to $110.00 from $95.00 on Wednesday, while maintaining a Buy rating on the shares. The stock has shown remarkable momentum, ...